Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Dasatinib-induced pleural effusions: a lymphatic network disorder?

Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA.

Am J Med Sci. 2009 Nov;338(5):414-7. doi: 10.1097/MAJ.0b013e3181ae9227.

PMID:
19838099
3.

Pleural effusions due to dasatinib.

Brixey AG, Light RW.

Curr Opin Pulm Med. 2010 Jul;16(4):351-6. doi: 10.1097/MCP.0b013e328338c486. Review.

PMID:
20375898
4.

Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?

Paydas S.

Crit Rev Oncol Hematol. 2014 Feb;89(2):242-7. doi: 10.1016/j.critrevonc.2013.10.005. Epub 2013 Oct 12. Review.

PMID:
24210599
5.

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.

Masiello D, Gorospe G 3rd, Yang AS.

J Hematol Oncol. 2009 Nov 12;2:46. doi: 10.1186/1756-8722-2-46. Review.

6.
7.

Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.

Shayani S.

Ther Drug Monit. 2010 Dec;32(6):680-7. doi: 10.1097/FTD.0b013e3181f4d9c5. Review.

PMID:
20864900
8.

Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.

Breccia M, Alimena G.

Expert Opin Drug Saf. 2010 Sep;9(5):713-21. doi: 10.1517/14740331003742935. Review.

PMID:
20722490
9.

New approved dasatinib regimen available for clinical use.

Snyder DS.

Expert Rev Anticancer Ther. 2009 Mar;9(3):285-92. doi: 10.1586/14737140.9.3.285. Review.

PMID:
19275507
10.

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.

Breccia M, Latagliata R, Stagno F, Luciano L, Gozzini A, Castagnetti F, Fava C, Cavazzini F, Annunziata M, Russo Rossi A, Pregno P, Abruzzese E, Vigneri P, Rege-Cambrin G, Sica S, Pane F, Santini V, Specchia G, Rosti G, Alimena G.

Haematologica. 2011 Oct;96(10):1457-61. doi: 10.3324/haematol.2011.041251. Epub 2011 Jun 17.

11.

Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.

Bergeron A, Réa D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P.

Am J Respir Crit Care Med. 2007 Oct 15;176(8):814-8. Epub 2007 Jun 28.

PMID:
17600277
12.

Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.

Eskazan AE, Soysal T, Ongoren S, Gulturk E, Ferhanoglu B, Aydin Y.

Haematologica. 2011 Mar;96(3):e15; author reply e16-7. doi: 10.3324/haematol.2011.040048. No abstract available.

13.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.

N Engl J Med. 2006 Jun 15;354(24):2531-41.

14.

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.

Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G.

Hematol Oncol. 2013 Jun;31(2):103-9. doi: 10.1002/hon.2020. Epub 2012 Jul 19. Erratum in: Hematol Oncol. 2013 Spe;31(3):169.

PMID:
22815278
15.

Dasatinib.

Lindauer M, Hochhaus A.

Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. Review.

PMID:
20072833
16.

Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.

Quintás-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, Cortes J.

J Clin Oncol. 2007 Sep 1;25(25):3908-14.

PMID:
17761974
17.

Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.

Kim D, Goh HG, Kim SH, Cho BS, Kim DW.

Int J Hematol. 2011 Oct;94(4):361-71. doi: 10.1007/s12185-011-0921-9. Epub 2011 Sep 8.

PMID:
21901399
18.

[Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].

Bjerrum OW, Dufva IH, Stentoft J, Hasselbalch HC.

Ugeskr Laeger. 2008 Jan 28;170(5):331-3. Danish.

PMID:
18252160
19.

Management of Bcr-Abl-positive leukemias with dasatinib.

Hochhaus A.

Expert Rev Anticancer Ther. 2007 Nov;7(11):1529-36. Review.

PMID:
18020922
20.

Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.

Ustun C, Randall N, Podgaetz E, Amin K, Dincer HE.

Thorax. 2015 Jul;70(7):701-4. doi: 10.1136/thoraxjnl-2015-206841. Epub 2015 May 2. No abstract available.

PMID:
25935168

Supplemental Content

Support Center